skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine

Original Research

(3507) Views  (515) Full article downloads

Authors: Marty Hinz, Alvin Stein, Thomas Uncini

Published Date February 2011 Volume 2011:3 Pages 19 - 24
DOI: http://dx.doi.org/10.2147/RRU.S16637

Marty Hinz1 Alvin Stein2 Thomas Uncini3
1Clinical Research, NeuroResearch Clinics Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3DBS Laboratories, Duluth, MN, USA

Background: The purpose of this paper is to present the results of statistical analysis of spot baseline urinary norepinephrine and epinephrine assays in correlation with spot baseline urinary serotonin and dopamine findings previously published by the authors. Our research indicates a need for physicians and decision-makers to understand the lack of validity of this type of spot baseline monoamine testing when using it in the decision-making process for neurotransmitter deficiency disorders.
Methods: Matched-pairs t-tests were performed for a group of subjects for whom spot baseline urinary norepinephrine and epinephrine assays were performed on samples collected on different days then paired by subject.
Results: The reported laboratory test results for urinary serotonin, dopamine, norepinephrine, and epinephrine, obtained on different days from the same subjects, differed significantly and were not reproducible.
Conclusion: Spot baseline monoamine assays, in subjects not suffering from a monoamine-secreting tumor, such as pheochromocytoma or carcinoid syndrome, are of no value in decision-making due to this day-to-day variability and lack of reproducibility. While there have been attempts to integrate spot baseline urinary monoamine assays into treatment of peripheral or central neurotransmitter-associated disease states, diagnosis of neurotransmitter imbalances, and biomarker applications, significant differences in day-to-day reproducibility make this impossible given the known science as it exists today.

Keywords: neurotransmitter testing, epinephrine, norepinephrine, dopamine, serotonin




 

Other articles by Dr Marty Hinz

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid management of Parkinson’s disease: a case study
Amino acid-responsive Crohn's disease: a case study
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Monoamine depletion by reuptake inhibitors
Neurotransmitter testing of the urine: a comprehensive analysis
Relative nutritional deficiencies associated with centrally acting monoamines
The discrediting of the monoamine hypothesis
The dual-gate lumen model of renal monoamine transport
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”


Readers of this article also read: